No connection

Search Results

BGLC vs BHP

BGLC
BioNexus Gene Lab Corp.
BEARISH
Price
$3.12
Market Cap
$7.4M
Sector
Basic Materials
AI Confidence
95%
BHP
BHP Group Limited
NEUTRAL
Price
$67.52
Market Cap
$173.45B
Sector
Basic Materials
AI Confidence
72%

Valuation

P/E Ratio
BGLC
--
BHP
19.07
Forward P/E
BGLC
--
BHP
15.45
P/B Ratio
BGLC
0.82
BHP
7.19
P/S Ratio
BGLC
0.78
BHP
3.38
EV/EBITDA
BGLC
-1.26
BHP
15.39

Profitability

Gross Margin
BGLC
14.77%
BHP
82.21%
Operating Margin
BGLC
-30.26%
BHP
37.7%
Profit Margin
BGLC
-24.27%
BHP
17.59%
ROE
BGLC
-28.35%
BHP
21.99%
ROA
BGLC
-16.43%
BHP
11.02%

Growth

Revenue Growth
BGLC
-3.3%
BHP
-8.2%
Earnings Growth
BGLC
--
BHP
-34.0%

Financial Health

Debt/Equity
BGLC
0.03
BHP
0.49
Current Ratio
BGLC
8.3
BHP
1.46
Quick Ratio
BGLC
6.81
BHP
1.06

Dividends

Dividend Yield
BGLC
--
BHP
3.26%
Payout Ratio
BGLC
0.0%
BHP
69.9%

AI Verdict

BGLC BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial health with a Piotroski F-Score of 0/9, indicating severe deterioration in fundamental performance. Despite a low Price/Book and Price/Sales ratio suggesting potential value, the company is unprofitable with negative margins, declining revenue, and a disastrous five-year return of -98.9%. Strong liquidity ratios are overshadowed by an inability to generate profits or positive cash flow, while insider sentiment is neutral at best. The absence of Altman Z-Score and Graham Number prevents definitive valuation anchoring, but overwhelming evidence points to operational distress and high investment risk.

Strengths
Exceptionally high Current Ratio (8.30) indicating strong short-term liquidity
Very low Debt/Equity ratio (0.03) suggesting minimal leverage risk
Quick Ratio of 6.81 reflects substantial liquid assets relative to liabilities
Risks
Piotroski F-Score of 0/9 signals extreme financial weakness and high risk of continued underperformance
Negative profit and operating margins (-24.27%, -30.26%) show persistent unprofitability
Revenue declining YoY by 3.30% amid sector peers growing on average 18.78%
BHP NEUTRAL

BHP's Piotroski F-Score of 6/9 indicates stable financial health, but the absence of an Altman Z-Score limits distress risk assessment. The stock trades significantly above its Graham Number of $27.35 and intrinsic value of $24.78, reflecting a substantial premium. Despite strong profitability metrics like 37.7% operating margin and 21.99% ROE, earnings and revenue growth are sharply negative year-over-year. Analysts consensus is a hold with a $57.00 target, below current price, suggesting limited upside.

Strengths
High operating margin of 37.70% indicates strong cost control and pricing power
ROE of 21.99% exceeds sector average significantly, signaling efficient equity use
Debt/Equity of 0.49 is below sector average of 0.63, indicating conservative leverage
Risks
Revenue growth down 8.20% YoY and earnings down 34.00%, indicating deteriorating fundamentals
P/E of 19.07 is high relative to earnings contraction, increasing valuation risk
Price/Book of 7.19 is extremely elevated, suggesting overvaluation relative to book value

Compare Another Pair

BGLC vs BHP: Head-to-Head Comparison

This page compares BioNexus Gene Lab Corp. (BGLC) and BHP Group Limited (BHP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile